Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | CA2 | P00918 | 3/20 | 0.48 |
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | CA9 | Q16790 | 2/20 | 0.48 |
| ▸ | CA5A | P35218 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 5/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | MLYCD | O95822 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | KIF11 | P52732 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.36 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL497773 | 0.87 | HSD11B1 (0.43) | TSHRHSD11B1KIF11ALDH1A1 | |
| SCHEMBL8015827 | 0.82 | TSHR (0.60) | TSHRCA2CA1CA9CA5A | |
| SCHEMBL822242 | 0.79 | TSHR (0.55) | TSHRCA2CA1CA9CA5A | |
| SCHEMBL16277011 | 0.79 | TSHR (0.55) | TSHRACHETDP1MAPTNPC1 | |
| SCHEMBL21497367 | 0.79 | HSD11B1 (0.39) | TSHRCA2CA1CA9CA5A | |
| SCHEMBL91414 | 0.79 | TSHR (0.55) | TSHRCA2CA1CA9CA5A | |
| SCHEMBL9598862 | 0.79 | TSHR (0.55) | TSHRCA2CA1CA9CA5A | |
| SCHEMBL17816159 | 0.79 | TSHR (0.55) | TSHRCA2CA1CA9CA5A | |
| SCHEMBL25012720 | 0.78 | TSHR (0.55) | TSHRCA2CA1CA9CA5A | |
| SCHEMBL5753370 | 0.78 | TSHR (0.55) | TSHRCA2CA1CA9CA5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240224783-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2024-07-04 | — | — | US | disclosed |
| US-20240218004-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2024-07-04 | — | — | US | disclosed |
| US-20240209013-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240023435-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2024-01-18 | — | — | US | disclosed |
| US-20230399350-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2023-12-14 | — | — | US | disclosed |
| US-20230371358-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230365606-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230357296-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2023-11-09 | — | — | US | disclosed |
| US-20230348510-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2023-11-02 | — | — | US | disclosed |
| US-20230348509-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2023-11-02 | — | — | US | disclosed |
| CN-110776453-A | Antiviral drug for treatment of arenavirus infection | 奇尼塔四有限责任公司 | 2020-02-11 | — | — | CN | disclosed |
| CN-110698408-A | Antiviral drug for treatment of arenavirus infection | 奇尼塔四有限责任公司 | 2020-01-17 | — | — | CN | disclosed |
| WO-2020007807-A1 | LACTATE ENHANCING COMPOUNDS AND USES THEREOF | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) | 2020-01-09 | — | — | WO | disclosed |
| US-10000486-B2 | Antiviral drugs for treatment of arenavirus infection | KINETA VIRAL HEMORRHAGIC FEVER, LLC (US) | 2018-06-19 | — | — | US | disclosed |
| EP-2814486-B1 | ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION | KINETA FOUR LLC (US) | 2018-04-11 | — | — | EP | disclosed |
| US-20170137422-A1 | ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION | Kineta Four, LLC (US) | 2017-05-18 | — | — | US | disclosed |
| US-9498470-B2 | Antiviral drugs for treatment of arenavirus infection | Kineta Four, LLC (US) | 2016-11-22 | — | — | US | disclosed |
| WO-2015087993-A1 | OXAZOLIDINE AND OXAZINANE DERIVATIVES | 大正製薬株式会社 | 2015-06-18 | — | — | WO | disclosed |
| US-20150023916-A1 | ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION | SIGA TECHNOLOGIES INC. (US) | 2015-01-22 | — | — | US | disclosed |
| WO-2013137479-A1 | DECAHYDROQUINOXALINE DERIVATIVES AND ANALOGS THEREOF | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10000486-B2 | Antiviral drugs for treatment of arenavirus infection | EIF2AK2, ZC3HAV1, SARS1 | TSHR 4793/4885CA2 3525/4885CA1 3327/4885 |
| US-20230399350-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | OCIAD1, OCIAD2, OSBP | TSHR 4267/4885CA2 4416/4885CA1 4284/4885 |
| US-20150023916-A1 | ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION | EIF2AK2, ZC3HAV1, SARS1 | TSHR 4793/4885CA2 3525/4885CA1 3327/4885 |
| US-20170137422-A1 | ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION | EIF2AK2, ZC3HAV1, SARS1 | TSHR 4793/4885CA2 3525/4885CA1 3327/4885 |
| US-20230357296-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | OPRD1, OXER1, LBR | TSHR 661/4885CA2 2821/4885CA1 2590/4885 |
| US-20240224783-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | OCIAD2, OCIAD1, ICOSLG | TSHR 2736/4885CA2 4584/4885CA1 4821/4885 |
| US-20240209013-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | OCIAD2, SSB, L1CAM | TSHR 1035/4885CA2 1889/4885CA1 2001/4885 |
| US-20230348510-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | LBR, OXER1, OXSR1 | TSHR 312/4885CA2 3411/4885CA1 2612/4885 |
| US-20230348509-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | MLX, OCIAD1, LBR | TSHR 923/4885CA2 2562/4885CA1 2901/4885 |
| US-20230371358-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | LIFR, SOD1, ROS1 | TSHR 189/4885CA2 3295/4885CA1 1814/4885 |
| US-20230365606-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | OXER1, OPRD1, OXSR1 | TSHR 159/4885CA2 3314/4885CA1 2587/4885 |
| US-20240218004-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | OCIAD1, OCIAD2, CCND2 | TSHR 1707/4885CA2 2074/4885CA1 1733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.